December 6, 2017 — Medexprim announced its Radiomics Enabler, meant to enhance medical images archives for research, is now released as open source software under a GNU Affero General Public License v3 (AGPLv3).
Quantitative medical imaging biomarkers discovery (radiomics) and cognitive imaging analytics are transforming radiology, according to Medexprim. These developments require that researchers access large amounts of imaging data, sufficient in quality, quantity and diversity. These data exist and are stored by hospitals in clinical picture archiving and communication systems (PACS). However, the exploitation of these resources is hampered by the tedious task of selecting, extracting and de-identifying relevant image sequences.
Medexprim’s Radiomics Enabler is an ETL (Extract-Transform-Load) for medical imaging. It automates the qualification and extraction of relevant imaging sequences from any PACS, for secondary use in research. The solution can be integrated within a clinical data warehouse (CDW) to create unified and harmonized patient cohorts, with complete access to their clinical and imaging data. Instead of spending months in manual/low-value tasks extracting and preparing data, researchers can focus on their key expertise in data science and medicine.
Medexprim chose to distribute its software as open-source in order to foster a fast adoption by the imaging community at large, and specifically by research groups working on radiomics or developing artificial intelligence (AI) algorithms. The company’s ultimate goal is to optimize translational research and accelerate access to personalized medicine for all patients. This move adds to the range of open source solutions available for research in biomedical imaging, among which the Radiological Society of North America’s (RSNA) Clinical Trials Processor (CTP) or XNAT, for which Medexprim also provides commercial support.
Radiomics Enabler was featured in Medexprim’s booth at the 2017 RSNA Annual Meeting, Nov. 26-Dec. 1 in Chicago.
For more information: www.medexprim.com
March 11, 2026 
